Literature DB >> 17393520

Genome-wide molecular profiles of HCV-induced dysplasia and hepatocellular carcinoma.

Elisa Wurmbach1, Ying-bei Chen, Greg Khitrov, Weijia Zhang, Sasan Roayaie, Myron Schwartz, Isabel Fiel, Swan Thung, Vincenzo Mazzaferro, Jordi Bruix, Erwin Bottinger, Scott Friedman, Samuel Waxman, Josep M Llovet.   

Abstract

UNLABELLED: Although HCC is the third-leading cause of cancer-related deaths worldwide, there is only an elemental understanding of its molecular pathogenesis. In western countries, HCV infection is the main etiology underlying this cancer's accelerating incidence. To characterize the molecular events of the hepatocarcinogenic process, and to identify new biomarkers for early HCC, the gene expression profiles of 75 tissue samples were analyzed representing the stepwise carcinogenic process from preneoplastic lesions (cirrhosis and dysplasia) to HCC, including 4 neoplastic stages (very early HCC to metastatic tumors) from patients with HCV infection. We identified gene signatures that accurately reflect the pathological progression of disease at each stage. Eight genes distinguish between control and cirrhosis, 24 between cirrhosis and dysplasia, 93 between dysplasia and early HCC, and 9 between early and advanced HCC. Using quantitative real-time reverse-transcription PCR, we validated several novel molecular tissue markers for early HCC diagnosis, specifically induction of abnormal spindle-like, microcephaly-associated protein, hyaluronan-mediated motility receptor, primase 1, erythropoietin, and neuregulin 1. In addition, pathway analysis revealed dysregulation of the Notch and Toll-like receptor pathways in cirrhosis, followed by deregulation of several components of the Jak/STAT pathway in early carcinogenesis, then upregulation of genes involved in DNA replication and repair and cell cycle in late cancerous stages.
CONCLUSION: These findings provide a comprehensive molecular portrait of genomic changes in progressive HCV-related HCC.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17393520     DOI: 10.1002/hep.21622

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  337 in total

1.  Hepatitis C virus-induced cancer stem cell-like signatures in cell culture and murine tumor xenografts.

Authors:  Naushad Ali; Heba Allam; Randal May; Sripathi M Sureban; Michael S Bronze; Ted Bader; Shahid Umar; Srikant Anant; Courtney W Houchen
Journal:  J Virol       Date:  2011-09-21       Impact factor: 5.103

2.  A polymorphism that delays fibrosis in hepatitis C promotes alternative splicing of AZIN1, reducing fibrogenesis.

Authors:  Andrew J Paris; Zohar Snapir; Cindy D Christopherson; Shirley Y Kwok; Ursula E Lee; Zahra Ghiassi-Nejad; Peri Kocabayoglu; John J Sninsky; Josep M Llovet; Chaim Kahana; Scott L Friedman
Journal:  Hepatology       Date:  2011-12       Impact factor: 17.425

3.  Hdac3 is essential for the maintenance of chromatin structure and genome stability.

Authors:  Srividya Bhaskara; Sarah K Knutson; Guochun Jiang; Mahesh B Chandrasekharan; Andrew J Wilson; Siyuan Zheng; Ashwini Yenamandra; Kimberly Locke; Jia-Ling Yuan; Alyssa R Bonine-Summers; Christina E Wells; Jonathan F Kaiser; M Kay Washington; Zhongming Zhao; Florence F Wagner; Zu-Wen Sun; Fen Xia; Edward B Holson; Dineo Khabele; Scott W Hiebert
Journal:  Cancer Cell       Date:  2010-11-16       Impact factor: 31.743

4.  Prognostic value of purinergic P2X7 receptor expression in patients with hepatocellular carcinoma after curative resection.

Authors:  Haiou Liu; Weisi Liu; Zheng Liu; Yidong Liu; Weijuan Zhang; Le Xu; Jiejie Xu
Journal:  Tumour Biol       Date:  2015-02-27

Review 5.  Current biomarkers for hepatocellular carcinoma: Surveillance, diagnosis and prediction of prognosis.

Authors:  Kerstin Schütte; Christian Schulz; Alexander Link; Peter Malfertheiner
Journal:  World J Hepatol       Date:  2015-02-27

6.  MAPK/ERK signaling pathway-induced hyper-O-GlcNAcylation enhances cancer malignancy.

Authors:  Xinling Zhang; Leina Ma; Jieqiong Qi; Hui Shan; Wengong Yu; Yuchao Gu
Journal:  Mol Cell Biochem       Date:  2015-08-29       Impact factor: 3.396

7.  From liver cirrhosis to HCC.

Authors:  Luigi Bolondi; Laura Gramantieri
Journal:  Intern Emerg Med       Date:  2011-10       Impact factor: 3.397

8.  POU2F1 promotes growth and metastasis of hepatocellular carcinoma through the FAT1 signaling pathway.

Authors:  Hong Yan Zhu; Guan Yi Cao; Shi Ping Wang; Yu Chen; Guo Dong Liu; Yu Jie Gao; Jian Ping Hu
Journal:  Am J Cancer Res       Date:  2017-08-01       Impact factor: 6.166

9.  SALL4 immunoreactivity predicts prognosis in Western hepatocellular carcinoma patients but is a rare event: a study of 236 cases.

Authors:  Ta-Chiang Liu; Neeta Vachharajani; William C Chapman; Elizabeth M Brunt
Journal:  Am J Surg Pathol       Date:  2014-07       Impact factor: 6.394

10.  Proteomic dissection of cell type-specific H2AX-interacting protein complex associated with hepatocellular carcinoma.

Authors:  Xiaoli Yang; Peng Zou; Jun Yao; Dong Yun; Huimin Bao; Ruyun Du; Jing Long; Xian Chen
Journal:  J Proteome Res       Date:  2010-03-05       Impact factor: 4.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.